European Companies Search Engine
EU funding (€2,575,810): Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) during Ebola virus infection in non-human primates humans Hor 1 Nov 2014 EU Research and Innovation programme "Horizon"
Text
Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) during Ebola virus infection in non-human primates humans
The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.
Funded Companies:
| Company name | Funding amount |
| Bernhard-Nocht-Institut Fuer Tropenmedizin | €64,250 |
| Centre Technologique Nouvelle-Aquitaine Composites & Materiaux Avances | €477,262 |
| Department of Health | €64,250 |
| Drug Discovery Factory B.V. | €127,063 |
| Ecole Normale Superieure de Lyon | €142,500 |
| Fondation Pour L Institut DE Hautes Etudes Internationales ET Du Developpement | €0.00 |
| Institut National de la Sante et de la Recherche Medicale | €1,240,726 |
| Institut Pasteur | €74,025 |
| Ruprecht-Karls-Universitaet Heidelberg | €86,250 |
| Universite Cheikh Anta Diop DE Dakar | €134,375 |
| Universite d'AIX Marseille | €88,500 |
| Universiteit Utrecht | €4,250.00 |
| Universiteit Van Amsterdam | €72,359 |
Source: https://cordis.europa.eu/project/id/666092
The filing refers to a past date, and does not necessarily reflect the current state.